IBDEI3AJ ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,52519,2)
 ;;=^5002633
 ;;^UTILITY(U,$J,358.3,52520,0)
 ;;=E11.3211^^194^2540^22
 ;;^UTILITY(U,$J,358.3,52520,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52520,1,3,0)
 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Rt Eye
 ;;^UTILITY(U,$J,358.3,52520,1,4,0)
 ;;=4^E11.3211
 ;;^UTILITY(U,$J,358.3,52520,2)
 ;;=^5138331
 ;;^UTILITY(U,$J,358.3,52521,0)
 ;;=E11.3212^^194^2540^23
 ;;^UTILITY(U,$J,358.3,52521,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52521,1,3,0)
 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Lt Eye
 ;;^UTILITY(U,$J,358.3,52521,1,4,0)
 ;;=4^E11.3212
 ;;^UTILITY(U,$J,358.3,52521,2)
 ;;=^5138332
 ;;^UTILITY(U,$J,358.3,52522,0)
 ;;=E11.3213^^194^2540^24
 ;;^UTILITY(U,$J,358.3,52522,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52522,1,3,0)
 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Bilat
 ;;^UTILITY(U,$J,358.3,52522,1,4,0)
 ;;=4^E11.3213
 ;;^UTILITY(U,$J,358.3,52522,2)
 ;;=^5138333
 ;;^UTILITY(U,$J,358.3,52523,0)
 ;;=E11.40^^194^2540^10
 ;;^UTILITY(U,$J,358.3,52523,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52523,1,3,0)
 ;;=3^DM Type 2 w/ Diab Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,52523,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,52523,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,52524,0)
 ;;=E11.51^^194^2540^12
 ;;^UTILITY(U,$J,358.3,52524,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52524,1,3,0)
 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,52524,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,52524,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,52525,0)
 ;;=E11.52^^194^2540^11
 ;;^UTILITY(U,$J,358.3,52525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52525,1,3,0)
 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,52525,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,52525,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,52526,0)
 ;;=E11.620^^194^2540^5
 ;;^UTILITY(U,$J,358.3,52526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52526,1,3,0)
 ;;=3^DM Type 2 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,52526,1,4,0)
 ;;=4^E11.620
 ;;^UTILITY(U,$J,358.3,52526,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,52527,0)
 ;;=E11.36^^194^2540^4
 ;;^UTILITY(U,$J,358.3,52527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52527,1,3,0)
 ;;=3^DM Type 2 w/ Diab Cataract
 ;;^UTILITY(U,$J,358.3,52527,1,4,0)
 ;;=4^E11.36
 ;;^UTILITY(U,$J,358.3,52527,2)
 ;;=^5002642
 ;;^UTILITY(U,$J,358.3,52528,0)
 ;;=I10.^^194^2541^1
 ;;^UTILITY(U,$J,358.3,52528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52528,1,3,0)
 ;;=3^Essential/Primary Hypertension
 ;;^UTILITY(U,$J,358.3,52528,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,52528,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,52529,0)
 ;;=I11.0^^194^2541^12
 ;;^UTILITY(U,$J,358.3,52529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52529,1,3,0)
 ;;=3^Hypertensive Heart Disease w/ Heart Failure
 ;;^UTILITY(U,$J,358.3,52529,1,4,0)
 ;;=4^I11.0
 ;;^UTILITY(U,$J,358.3,52529,2)
 ;;=^5007063
 ;;^UTILITY(U,$J,358.3,52530,0)
 ;;=I11.9^^194^2541^13
 ;;^UTILITY(U,$J,358.3,52530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52530,1,3,0)
 ;;=3^Hypertensive Heart Disease w/o Heart Failure
 ;;^UTILITY(U,$J,358.3,52530,1,4,0)
 ;;=4^I11.9
 ;;^UTILITY(U,$J,358.3,52530,2)
 ;;=^5007064
 ;;^UTILITY(U,$J,358.3,52531,0)
 ;;=I12.0^^194^2541^5
 ;;^UTILITY(U,$J,358.3,52531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,52531,1,3,0)
 ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
